Robert Marcus
Stock Analyst at JP Morgan
(1.39)
# 3,522
Out of 5,072 analysts
22
Total ratings
47.06%
Success rate
-1.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Maintains: Neutral | $265 → $275 | $295.96 | -7.08% | 4 | Nov 6, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $13.11 | +472.08% | 2 | Dec 17, 2021 | |
| BDX Becton, Dickinson and Company | Downgrades: Neutral | $265 | $193.90 | +36.67% | 10 | Aug 6, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $105.39 | -52.56% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $145.75 | -89.71% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $36.03 | +58.20% | 2 | Jul 29, 2020 |
Penumbra
Nov 6, 2025
Maintains: Neutral
Price Target: $265 → $275
Current: $295.96
Upside: -7.08%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $13.11
Upside: +472.08%
Becton, Dickinson and Company
Aug 6, 2021
Downgrades: Neutral
Price Target: $265
Current: $193.90
Upside: +36.67%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $105.39
Upside: -52.56%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $145.75
Upside: -89.71%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $36.03
Upside: +58.20%